U klikt door naar een site van derden.

GSK aanvaardt betreffende het gebruik van websites in beheer door derden, inclusief hun inhoud, geen enkele verantwoordelijkheid.

Verder

Ga terug

Product menu

NA

Which patients may particularly benefit from EXDENSUR?

Earlyi treatment initiation in severe, uncontrolled Type 2 asthma can reduce exacerbations and also decrease overall disease burden in patients with multiple comorbidities.a-d,1-3

Exacerbations

When exacerbations are the main problem

Comorbid CRSwNP

Reduce disease activity despite multimorbidity

The first and only biologic for severe, uncontrolled Type 2 asthma with an ultra-long duration of action that can reduce exacerbations.a-d,1-3

EXDENSUR may be appropriate for:e

Teaser Biologika‑naive Patienten mit schwerem Asthma

Biologic-naïve patients with severe asthma

Teaser Typ‑2‑Inflammation charakterisiert durch Eosinophile

Type 2 inflammation characterized by elevated eosinophils

Teaser Asthma

Inadequate asthma control despite high-dose ICS/LABA therapy

Earlyi treatment initiation may sustainably reduce both exacerbations and the need for oral corticosteroids (OCS) in severe asthma.3-6

Thanks to its ultra-long duration of action, EXDENSUR may contribute to improved asthma control while reducing exacerbations.4

Frau mit Blumenstrauß

Hypothetical Patient

  • Bio-naïve patient
  • 44 years old
  • Diagnosis: 2 years ago
  • Uncontrolled asthma with type 2 inflammation characterised by BEC (ACT: 13 points)
  • 2 exacerbations in the past year, one of which required hospitalization; both treated with OCS pulse therapy
  • Known triggers: cold, stress, dry air
44 years old
  • High-dose ICS/LABA maintenance therapy
  • SABA as needed
  • Repeated OCS bursts during exacerbations
  • Blood eosinophils:
    • Historical count: 332 EOS/µL
    • Current count: 182 EOS/µL
  • FeNO: 47 ppb
  • FEV1: below predicted
  • Total IgE: 250 kU/L

Sustained reduction of disease burden with ultra-long duration of action1,7

Earlyi treatment initiation in severe asthma with comorbid CRSwNP may sustainably reduce disease burden.3,7

EXDENSUR offers the possibility to significantly influence disease progression in these patients.1–4,7

Frau steht unter blühenden Bäumen

Hypothetical Patient

  • Bio-naïve patient
  • 65 years old
  • Diagnosed 10 years ago (late-onset asthma)
  • Uncontrolled Type 2 asthma
  • Comorbid CRSwNP
  • 3 exacerbations in the last year with repeated OCS bursts
  • Nasal obstruction
  • Postnasal drip
  • Facial pressure
  • Poor sleep quality
  • Frequent coughing
  • High-dose ICS/LABA maintenance therapy
  • SABA as needed
  • Intranasal corticosteroids
  • Saline nasal irrigation
  • Blood eosinophils: 290 EOS/µL
  • FeNO: 29 ppb


More about Exdensur

Teaser Wirkansatz

Mechanism of Action

  • Designed for ultra-long-lasting control of type 2 inflammation10,11
  • Efficient IL-5 blockade1,11
  • Prolonged serum half-lifef,g,1

Learn more
Teaser Dosierung

Dosing

Only 2 injections per year for ultra-long-lasting efficacy.h,1

More about Dosing
Teaser Sicherheit

Safety

  • Safety profile comparable to placebo.1
  • 99% of patients continued treatment throughout the study.8–10

Learn more

  • Abbreviations

    ACT = Asthma Control Test; CRSwNP = Chronic Rhinosinusitis with Nasal Polyps; BEC = Blood Eosinophil Count; Fc = Crystallizable Fragment Region; FeNO = Fractional Exhaled Nitric Oxide; ICS = Inhaled Corticosteroids; IgE = Immunoglobulin E; IL = Interleukin; LABA = Long-Acting Beta-2 Agonist; OCS = Oral Corticosteroids; SABA = Short-Acting Beta-2 Agonist; YTE = Mutation (M252Y/S254T/T256E), a triple amino acid substitution in the Fc region of antibodies.

  • Footnotes

    a Characterized by eosinophils.

    b Defined as a worsening of asthma requiring one of the following: Systemic corticosteroids (intravenous or oral) for ≥ 3 days, or a single intramuscular dose; or Hospitalization or an emergency department visit; or At least a doubling of the existing maintenance dose of systemic corticosteroids for ≥ 3 days.1

    c Mean annual exacerbation rate in the previous year: SWIFT-1: 2.2; SWIFT-2: 2.7.1

    d Annual exacerbations: SWIFT-1: 0.46 with EXDENSUR (n=250) vs. 1.11 with placebo (n=132); p<0.001. SWIFT-2: 0.56 with EXDENSUR (n=252) vs. 1.08 with placebo (n=128); 48% reduction; p<0.001.2

    e EXDENSUR (depemokimab) is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids(ICS) plus another asthma controller.1

    f Compared with the serum half-life of mepolizumab and benralizumab (16–22 days and 15.5 days, respectively).2,3

    g The YTE region is a modified part of an antibody that contributes to a longer duration in the body by slowing its degradation.1

    h One injection every 26 weeks.

    i The use of the term "early" does not imply that a statistically significant benefit of earlier treatment initiation has been demonstrated. Rather, it reflects a clinically relevant interpretation of the available evidence, including findings suggesting an opportunity for biologic initiation in patients with shorter disease duration and before progression to high-dose ICS.

PM-BE-DEPE-WCNT-260014 - September 2026